Merck Units To Pay $44M In Rebif Whistleblower Suit
By Martin Bricketto · May 4, 2011, 5:53 PM EDT
Merck KGaA affiliates have agreed to pay $44.3 million to resolve a whistleblower's allegations that they bought off health care providers to promote or prescribe the multiple sclerosis drug Rebif, resulting...
To view the full article, register now.